期刊文献+

腋窝淋巴结转移对浸润性乳腺癌预后的影响 被引量:7

Influence of Axilla Lymphatic Metastasis to Prognosis of Infiltrating Breast Cancer
下载PDF
导出
摘要 目的:腋窝淋巴结(ALN)转移数目是影响浸润性乳腺癌预后最重要的因素,本研究明确淋巴结转移(LNM)数目与无瘤生存期的关系,并将其作为判断乳腺癌预后的标志。方法:180例行全乳+ALN I、II平面解剖术病例,摘取全数LN作连续6张切片,由病理切片报告浸润癌最大径。并根据PN和PT结果,选择化疗和(或)内分泌治疗方案。记录乳腺癌患者的年龄、肿瘤大小、ALN检查数、转移数。分别用t检验、χ2检验进行统计学分析。按Kaplan-Meier方法计算生存率,并对其进行Log-rank检验。结果:180例中,95例有ALNM,ALNM发生率为53%。其中N085例;N152例;N220例;N323例。ALNM数随肿瘤大小增加而升高。总的5年无瘤生存率88%,无ALNM者,5年无瘤生存率为99%;一旦出现ALNM,5年无瘤生存率则降至79%(P<0.01)。结论:腋窝淋巴结状况是乳腺癌重要的预后因素。淋巴结转移数目、孕激素受体是判断预后的指标。切除淋巴结数应超过10枚,以便准确N分期。 Objective : The number of axillary lymph node (ALN) metastasis is the most impor- tant prognostic factor in the patients with infiltrating breast cancer. The purpose of this study is to de- termine the relationship between the number of nodal metastasis and the survival time without tu- mor, and make it to be a sign of the breast cancer prognosis. Methods: 180 cases with full breast+ ALN Ⅰ, Ⅱ plane dissection, picked up all the LN, consecutively made 6 slices, reported the maxi- mum gauge with pathological slice. In accordance with pN and pT results, chose the chemo-treat- ment and or or incretion treatment. Recorded the breast cancer patients' age, tumor size, ALN checked number, metastasis number. Carried out stastieal analysis with t test and Z2 test. Calculat- ed the survival rate with Kaplan-Meier method, and carried out log-rank test. Results: In 180 cas- es, 95 cases had ALNM, the occuring rate of ALNM was 53%. Among it, No 85 cases, Nt 52 cases, N2 20 cases, N3 23 cases. The number of ALNM increased as the tumor size going up. The general survival rate in 5 years without tumor was 88%, the patients without ALNM, 5 years survival rate without tumor was 99% ; once appeared ALNM, 5 years survival rate without tumor decreased to 79% (P 〈 0.01 ). Conclusion : The condition of axilla lymph node is an important factor to prognosis of breast cancer. The number of lymphatic metastasis and the progesterone receptor are the index for prognosis. The cutted number of lymphnode should be more than 10, for accurately judging the N level.
出处 《江汉大学学报(自然科学版)》 2013年第1期88-90,共3页 Journal of Jianghan University:Natural Science Edition
关键词 乳腺癌 淋巴结 转移 预后 breast cancer lymph node metastasis prognosis
  • 相关文献

参考文献6

  • 1Fisher E R,Remond C,Fisher B,et al. Pathologic find-ings from the National Surgical Adjuvant Breast Project(Protocol no.4). Discriminants for five-year survival[J]. Cancer, 1980,46(4 Suppl) :908-918.
  • 2Jatoi I,Hilsenbeck S G, Clark G M, et al. Significanceof axillary lymph node metastasis in primary breast can-cer[j]. J Clin Oncol, 1999,17( 10) :3365.
  • 3Weir L, Speers C, D'yachkova Y, et al. Prognostic sig-nificance of the number of axillary lymph nodes re-moved in patients with node-negative breast cancer [J].J Clin Oncol,2002,20(7) : 1793-1799.
  • 4彭开勤,刘丽江,张应天,刘文,龚少敏,全卓勇,邵永胜.一种新的胃癌淋巴结分期方案[J].中华外科杂志,2001,39(12):908-910. 被引量:17
  • 5Carter C L, Allen C, Henson D E, et al. Relation of tu-mor size, lymph node status, and survival in 24,740breast cancer cases[J]. Cancer, 1989,63( l) : 181-187.
  • 6Mousumi B, Julie G, Eun Y S, et al. Tree-based modelfor breast cancer prognstication[J]. J Clin Oncol, 2004,22:2567-2575.

二级参考文献3

共引文献16

同被引文献63

  • 1须捷平,徐曙光,张云,俞羚,吴连明,殷志强,曹晖.三阴性乳腺癌的临床病理特征和预后影响因素分析[J].上海交通大学学报(医学版),2011,31(5):637-641. 被引量:18
  • 2张瑶,沈伟生.加味二仙汤治疗乳腺癌综合治疗后类更年期综合征32例[J].山东中医药大学学报,2007,31(2):137-138. 被引量:10
  • 3陈蕾,徐绮腻,郑瑾,林佩娟,张舜芬.乳腺癌临床特征与预后分析[J].中华肿瘤防治杂志,2007,14(15):1159-1162. 被引量:8
  • 4F.L.Greene,D.L.Page,I.D.Fleming,et al.AJCC肿瘤分期手册[M].6版.北京:中国医药科技出版社,2009:219-228.
  • 5Siegel R,Naishadham D,Jemal A. Cancer statistics,2012[J].{H}CA-A Cancer Journal for Clinicians,2012,(01):10-29.
  • 6Torchilin VP,Iakoubov LZ,Estrov Z. Antinuclear autoantibodies as potential antineoplastic agents[J].{H}Trends in Immunology,2001,(08):424-427.
  • 7Tavassoli FA,Devilee P. WHO classification of tumors:pathology and genetics of tumors of the breast and female genital organs[M].{H}Lyon:IARC Press,2003.
  • 8Levenson W. Biomarkers for early detection of breast cancer:what,when,and where[J].{H}Biochimica et Biophysica Acta,2007,(06):847-856.
  • 9Shin BK,Wang H,Hanash S. Proteomics approaches to uncover the repertoire of circulating biomarkers for breast cancer[J].{H}Journal of Mammary Gland Biology and Neoplasia,2002,(04):407-413.
  • 10Lu H,Goodell V,Disis ML. Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer[J].{H}Journal of Proteome Research,2008,(04):1388-1394.doi:10.1021/pr700818f.

引证文献7

二级引证文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部